Notably, although treatment with TRL had no effect on the inhibition of primary tumor formation in the pancreas (Fig. 5b), it significantly reduced the expression of COL17A1 and MMP2 (Fig. 5e, f). The gene discussed is MMP2; the disease is neoplasm.